Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections
- PMID: 15705637
- DOI: 10.1093/jac/dki022
Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections
Abstract
Objectives: The in vitro antifungal activity of posaconazole was compared with that of fluconazole and amphotericin B.
Materials and methods: A microdilution method (M27-A2) was used with 331 clinical yeast isolates.
Results: The geometric mean MICs of posaconazole, fluconazole and amphotericin B were 0.16, 0.91 and 0.15 mg/L, respectively. Posaconazole was markedly more active than fluconazole and was active against 9/11 fluconazole-resistant Candida albicans, and five Candida glabrata had an MIC of posaconazole of 16 mg/L.
Conclusions: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.
Similar articles
-
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06. Antimicrob Agents Chemother. 2006. PMID: 16723559 Free PMC article.
-
[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].Rev Esp Quimioter. 2003 Jun;16(2):227-32. Rev Esp Quimioter. 2003. PMID: 12973462 Spanish.
-
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13. Int J Antimicrob Agents. 2008. PMID: 18790613
-
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.Lancet Infect Dis. 2002 Feb;2(2):73-85. doi: 10.1016/s1473-3099(02)00181-0. Lancet Infect Dis. 2002. PMID: 11901654 Review.
-
Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.Eur J Med Chem. 2019 May 15;170:173-194. doi: 10.1016/j.ejmech.2019.03.020. Epub 2019 Mar 11. Eur J Med Chem. 2019. PMID: 30897396 Review.
Cited by
-
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.Antimicrob Agents Chemother. 2006 Mar;50(3):917-21. doi: 10.1128/AAC.50.3.917-921.2006. Antimicrob Agents Chemother. 2006. PMID: 16495251 Free PMC article.
-
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Drugs. 2009. PMID: 19275278 Review.
-
Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.Antimicrob Agents Chemother. 2016 May 23;60(6):3398-406. doi: 10.1128/AAC.00054-16. Print 2016 Jun. Antimicrob Agents Chemother. 2016. PMID: 27001815 Free PMC article.
-
Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies.Drug Deliv Transl Res. 2022 Mar;12(3):662-675. doi: 10.1007/s13346-021-00974-x. Epub 2021 Apr 8. Drug Deliv Transl Res. 2022. PMID: 33830458
-
Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.Drugs. 2008;68(7):993-1016. doi: 10.2165/00003495-200868070-00008. Drugs. 2008. PMID: 18457464 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
